96 related articles for article (PubMed ID: 20233777)
1. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice.
Vingsbo Lundberg C; Vaara T; Frimodt-Møller N; Vaara M
J Antimicrob Chemother; 2010 May; 65(5):981-5. PubMed ID: 20233777
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of carbapenemase-producing strains of Klebsiella pneumoniae and Escherichia coli to the direct antibacterial activity of NAB739 and to the synergistic activity of NAB7061 with rifampicin and clarithromycin.
Vaara M; Siikanen O; Apajalahti J; Frimodt-Møller N; Vaara T
J Antimicrob Chemother; 2010 May; 65(5):942-5. PubMed ID: 20167589
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity studies on novel polymyxin derivatives that carry only three positive charges.
Vaara M; Vaara T
Peptides; 2010 Dec; 31(12):2318-21. PubMed ID: 20868714
[TBL] [Abstract][Full Text] [Related]
4. Polymyxin derivatives NAB739 and NAB815 are more effective than polymyxin B in murine Escherichia coli pyelonephritis.
Vaara M; Vaara T; Vingsbo Lundberg C
J Antimicrob Chemother; 2018 Feb; 73(2):452-455. PubMed ID: 29149329
[TBL] [Abstract][Full Text] [Related]
5. Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents.
Vaara M; Fox J; Loidl G; Siikanen O; Apajalahti J; Hansen F; Frimodt-Møller N; Nagai J; Takano M; Vaara T
Antimicrob Agents Chemother; 2008 Sep; 52(9):3229-36. PubMed ID: 18591267
[TBL] [Abstract][Full Text] [Related]
6. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells.
Mingeot-Leclercq MP; Tulkens PM; Denamur S; Vaara T; Vaara M
Peptides; 2012 Jun; 35(2):248-52. PubMed ID: 22504013
[TBL] [Abstract][Full Text] [Related]
7. Broad-spectrum beta-lactams for treating experimental peritonitis in mice due to Escherichia coli producing plasmid-encoded cephalosporinases.
Vimont S; Aubert D; Mazoit JX; Poirel L; Nordmann P
J Antimicrob Chemother; 2007 Nov; 60(5):1045-50. PubMed ID: 17804425
[TBL] [Abstract][Full Text] [Related]
8. Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection.
Tan XX; Actor JK; Chen Y
Antimicrob Agents Chemother; 2005 Aug; 49(8):3203-7. PubMed ID: 16048926
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of the polymyxin-like peptide ranalexin in an experimental model of endotoxemia.
Ghiselli R; Giacometti A; Cirioni O; Orlando F; Mocchegiani F; Pacci AM; Scalise G; Saba V
J Surg Res; 2001 Oct; 100(2):183-8. PubMed ID: 11592790
[TBL] [Abstract][Full Text] [Related]
10. The polymyxin derivative NAB739 is synergistic with several antibiotics against polymyxin-resistant strains of Escherichia coli, Klebsiella pneumoniae and Acinetobacter baumannii.
Tyrrell JM; Aboklaish AF; Walsh TR; Vaara T; Vaara M
Peptides; 2019 Feb; 112():149-153. PubMed ID: 30586602
[TBL] [Abstract][Full Text] [Related]
11. Antisense phosphorodiamidate morpholino oligomer inhibits viability of Escherichia coli in pure culture and in mouse peritonitis.
Geller BL; Deere J; Tilley L; Iversen PL
J Antimicrob Chemother; 2005 Jun; 55(6):983-8. PubMed ID: 15872045
[TBL] [Abstract][Full Text] [Related]
12. Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock.
Giacometti A; Cirioni O; Ghiselli R; Orlando F; Kamysz W; Rocchi M; D'Amato G; Mocchegiani F; Silvestri C; Łukasiak J; Saba V; Scalise G
Peptides; 2005 Feb; 26(2):207-16. PubMed ID: 15629532
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of antibiotics on the autochthonous Escherichia coli of mice in the intestinal biofilm versus its planktonic phase.
Kétyi I
Acta Microbiol Immunol Hung; 1994; 41(2):189-95. PubMed ID: 7804722
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity studies on polymyxin derivatives carrying three positive charges only reveal a new class of compounds with strong antibacterial activity.
Vaara M; Vaara T; Tyrrell JM
Peptides; 2017 May; 91():8-12. PubMed ID: 28300674
[TBL] [Abstract][Full Text] [Related]
16. Novel derivatives of polymyxins.
Vaara M
J Antimicrob Chemother; 2013 Jun; 68(6):1213-9. PubMed ID: 23412346
[TBL] [Abstract][Full Text] [Related]
17. The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models.
Szabo D; Ostorhazi E; Binas A; Rozgonyi F; Kocsis B; Cassone M; Wade JD; Nolte O; Otvos L
Int J Antimicrob Agents; 2010 Apr; 35(4):357-61. PubMed ID: 20031377
[TBL] [Abstract][Full Text] [Related]
18. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Schaumann R; Blatz R; Beer J; Ackermann G; Rodloff AC
J Antimicrob Chemother; 2004 Feb; 53(2):318-24. PubMed ID: 14729746
[TBL] [Abstract][Full Text] [Related]
19. Excretion of the Polymyxin Derivative NAB739 in Murine Urine.
Vaara M; Vaara T; Kuka J; Sevostjanovs E; Grinberga S; Dambrova M; Liepinsh E
Antibiotics (Basel); 2020 Mar; 9(4):. PubMed ID: 32230751
[TBL] [Abstract][Full Text] [Related]
20. In-vitro antibiotic susceptibility of E. coli isolated from acute and chronic bovine mastitis with reference to clinical efficacy.
Søgaard H
Nord Vet Med; 1982; 34(7-9):248-54. PubMed ID: 6757854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
